Abstract:Introduction: Human tumors, including gastric cancer, frequently express high levels of epidermal growth factor receptors (EGFRs), which are associated with a poor prognosis. Targeted delivery of anticancer drugs to cancerous tissues shows potential in sparing unaffected tissues. However, it has been a major challenge for drug penetration in solid tumor tissues due to the complicated tumor microenvironment. Chemotherapy employing paclitaxel (PTX) is widely used for treating various kinds of cancer including gastric cancer.Methods: Recombinant protein anti-EGFR-iRGD consisting of an anti-EGFR VHH (the variable domain from the heavy chain of the antibody) fused to iRGD, a tumor-specific binding peptide with high permeability were expressed in E. coli BL21 (DE3) and purified by nickel-nitrilotriacetic acid affinity chromatography. We use tumor cell lines (2D), multicellular spheroids (3D), and mice to analyze the antitumor activity of recombinant protein. To investigate the ability of anti-EGFR-iRGD to improve other drugs (e.g. PTX) penetrating into tumor, we used multicellular spheroids and mice.Results: We have successfully constructed a recombinant protein named anti-EGFR-iRGD, a dual target of EGFR and integrin and high permeable protein. It could spread extensively throughout both the multicellular spheroids and the tumor mass. The recombinant protein anti-EGFR-iRGD also exhibited antitumor activity in tumor cell lines (2D), multicellular spheroids (3D), and mice. Moreover, we demonstrated the therapeutic efficacy of PTX combined with anti-EGFR-iRGD on monolayer cells (2D), multicellular spheroids (3D) and tumor-bearing mice for the first time.Conclusion: Our results provide impetus for further studies for potentially using iRGD based fusion protein anti-EGFR-iRGD with standard cytotoxic treatment regimens for enhancing therapy of gastric cancer patients.Figure: P-014 Introduction: Human tumors, including gastric cancer, frequently express high levels of epidermal growth factor receptors (EGFRs), which are associated with a poor prognosis. Targeted delivery of anticancer drugs to cancerous tissues shows potential in sparing unaffected tissues. However, it has been a major challenge for drug penetration in solid tumor tissues due to the complicated tumor microenvironment. Chemotherapy employing paclitaxel (PTX) is widely used for treating various kinds of cancer including gastric cancer. Methods: Recombinant protein anti-EGFR-iRGD consisting of an anti-EGFR VHH (the variable domain from the heavy chain of the antibody) fused to iRGD, a tumor-specific binding peptide with high permeability were expressed in E. coli BL21 (DE3) and purified by nickel-nitrilotriacetic acid affinity chromatography. We use tumor cell lines (2D), multicellular spheroids (3D), and mice to analyze the antitumor activity of recombinant protein. To investigate the ability of anti-EGFR-iRGD to improve other drugs (e.g. PTX) penetrating into tumor, we used multicellular spheroids and mice. Results: We have successfully constructed a recombinant protein named anti-EGFR-iRGD, a dual target of EGFR and integrin and high permeable protein. It could spread extensively throughout both the multicellular spheroids and the tumor mass. The recombinant protein anti-EGFR-iRGD also exhibited antitumor activity in tumor cell lines (2D), multicellular spheroids (3D), and mice. Moreover, we demonstrated the therapeutic efficacy of PTX combined with anti-EGFR-iRGD on monolayer cells (2D), multicellular spheroids (3D) and tumor-bearing mice for the first time. Conclusion: Our results provide impetus for further studies for potentially using iRGD based fusion protein anti-EGFR-iRGD with standard cytotoxic treatment regimens for enhancing therapy of gastric cancer patients. Figure: P-014

Tumor-penetrating Peptide Fused to a Pro-Apoptotic Peptide Facilitates Effective Gastric Cancer Therapy

A New Fusion Peptide Targeting Pancreatic Cancer and Inhibiting Tumor Growth.

Tumor-Penetrating Peptide Fused Egfr Single-Domain Antibody Enhances Cancer Drug Penetration into 3d Multicellular Spheroids and Facilitates Effective Gastric Cancer Therapy

A Tumor-Penetrating Recombinant Protein Anti-Egfr-irgd to Enchance Efficacy of Paclitaxel in 3D Multicellular Spheroids and Gastric Cancer in Vivo.

Abstract A20: A Tumor-Penetrating Recombinant Protein Anti-Egfr-irgd Enhance Efficacy of Antigen-Specific CTL in Gastric Cancer in Vivo

sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment

P-014A Tumor-penetrating Recombinant Protein Anti-Egfr-irgd Enhance Efficacy of Paclitaxel in 3D Multicellular Spheroids and Gastric Cancer in Vivo

A Novel Peptide (GX1) Homing to Gastric Cancer Vasculature Inhibits Angiogenesis and Cooperates with TNF Alpha in Anti-Tumor Therapy

RGD Peptides-Conjugated Pluronic Triblock Copolymers Encapsulated with AP-2α Expression Plasmid for Targeting Gastric Cancer Therapy in Vitro and in Vivo

Smart pH-Sensitive Nanogels for Enhancing Synergistic Anticancer Effects of Integrin αvβ3 Specific Apoptotic Peptide and Therapeutic Nitric Oxide

Two Birds, One Stone: Dual Targeting of the Cancer Cell Surface and Subcellular Mitochondria by the Galectin-3-binding Peptide G3-C12

An Auristatin-Based Peptide-Drug Conjugate Targeting Kita-Kyushu Lung Cancer Antigen 1 for Precision Chemoradiotherapy in Gastric Cancer.

Targeting Matrix Metalloproteinases And Endothelial Cells With A Fusion Peptide Against Tumor

Abstract 5487: An auristatin-based peptide-drug conjugate targeting Kita-Kyushu lung cancer antigen 1 for precision chemoradiotherapy in gastric cancer

Human Cytotoxic T-lymphocyte Membrane-Camouflaged Nanoparticles Combined with Low-Dose Irradiation: a New Approach to Enhance Drug Targeting in Gastric Cancer

Spatial distribution control of antimicrobial peptides through a novel polymeric carrier for safe and efficient cancer treatment

An In-Tether Chiral Center Modulates the Proapoptotic Activity of the KLA Peptide.

Local ablation of gastric cancer by reconstituted apolipoprotein B lipoparticles carrying epigenetic drugs

Anti-HER2 scFv-CCL19-IL7 recombinant protein inhibited gastric tumor growth in vivo

Tumor‑penetrating Peptide Fused EGFR Single‑domain Antibody Enhances Radiation Responses Following EGFR Inhibition in Gastric Cancer.

Bispecific tumor-penetrating protein anti-EGFR-iRGD efficiently enhances the infiltration of lymphocytes in gastric cancer.